Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS MUTATION
NRAS MUTATION - Associated Disease
- skin melanoma
- Source Database
- CIViC Evidence
- Description
- Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growth inhibition, tyrosine phosphorylation inhibition, cell cycle and apoptotic (Annexin V) assays.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1476
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/208
- Rating
- 1
- Evidence Type
- Predictive
- Disease
- Skin Melanoma
- Evidence Direction
- Supports
- Drug
- Amuvatinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24950457
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Amuvatinib | Sensitivity | true |